öλÔÓéÀֵǼÈë¿ÚÏÂÔØ

µ¼Ê¦ÐÕÃû£ºÕÔ´ºÑÞ
ÐÔ±ð£º
ÈËÆøÖ¸Êý£º151

ËùÊôԺУ£º´óÁ¬Ò½¿Æ´óѧ
ËùÊôԺϵ£º¼ìÑéҽѧԺ
Ö°³Æ£º½ÌÊÚ
µ¼Ê¦ÀàÐÍ£ºË¶µ¼
ÕÐÉúöλÔÓéÀֵǼÈë¿ÚÏÂÔØ£ºÁÙ´²¼ìÑéÕï¶Ïѧ
Ñо¿ÁìÓò£º OVCA1»ùÒòÍ»±ä¶Ôϸ°ûÉú³¤ÔöÖ³µÄÓ°Ï죬ÆäÔÚÂѳ²°©·¢Éú·¢Õ¹µÄ×÷Óü°¶ÔÂѳ²°©ÔçÆÚÕï¶ÏµÄ¼ÛÖµ£»... [Õ¹¿ª]


Ñо¿ÁìÓò£º OVCA1»ùÒòÍ»±ä¶Ôϸ°ûÉú³¤ÔöÖ³µÄÓ°Ï죬ÆäÔÚÂѳ²°©·¢Éú·¢Õ¹µÄ×÷Óü°¶ÔÂѳ²°©ÔçÆÚÕï¶ÏµÄ¼ÛÖµ£»OVCA1½µ½âµÄ;¾¶¼°Ó°ÏìÒòËØ£»Rap1GAPÓ빬¾±°©·¢Éú·¢Õ¹µÄ¹Øϵ¡¢×÷ÓûúÖÆ£»Rap1GAP¶þ¾ÛÌåÐγɶÔÆ书ÄܵÄÓ°Ïì¡£ [ÊÕÆð]




ͨѶ·½Ê½ :
µç×ÓÓʼþ£º**@qq.com


¸öÈ˼òÊö :
ÕÔ´ºÑÞ£¬²©Ê¿£¬½ÌÊÚ£¬Ë¶Ê¿Éúµ¼Ê¦¡£ÏÖÈδóÁ¬Ò½¿Æ´óѧ¼ìÑéҽѧԺҽѧ¼ìÑé×ÛºÏʵÑéÊÒÖ÷ÈΡ£1996Ä기ÈÕ±¾CRCÑÐÐÞҽѧ¼ìÑéÏà¹Ø¼¼ÊõºÍʵÑéÊÒÖʿعÜÀí£¬2002ÄêÒÔ·ÃÎÊѧÕßÉí·Ý¸°ºÉÀ¼The Universtity of Utrecht, Medical centerѧϰ£¬ÔÚBos JL½ÌÊÚʵÑéÊÒ½øÐÐСGµ°°×ÐźÅתµ¼¶ÔÕý³£ºÍÒ쳣ϸ°ûÓ°ÏìµÄÑо¿¡£2009-2011ÄêÈÎÖйú¿ÆѧԺ´óÁ¬»¯Ñ§ÎïÀíÑо¿Ëù¸ß¼¶·ÃÎÊѧÕß¡£Ö÷³Ö²ÎÓë¸÷¼¶¿ÆÑнÌѧ¿ÎÌâ¶àÏî¡£¸±Ö÷±à¼°²Î±àÈËÃñÎÀÉú³ö°æÉç¡¢¸ßµÈ½ÌÓý³ö°æÉçµÈ±¾¿Æ¹æ»®½Ì²Ä¡¶·Ö×ÓÕï¶Ïѧ¡·¡¶ÁÙ´²·Ö×ÓÉúÎïѧ¼ìÑé¡·¶à²¿¡£

¿ÆÑй¤×÷ :
ÔÚÑÐÏîÄ¿
ÁÉÄþÊ¡×ÔÈ»¿Æѧ»ù½ðÃæÉÏÏîÄ¿¡°°©OVCA1½á¹¹¹¦Äܸı估¶ÔÂѳ²°©ÔçÆÚÕï¶Ï¼ÛÖµµÄÑо¿£¬**¡±£¬ÏîÄ¿¸ºÔðÈË¡£
´ú±íÐÔÎÄÕ£¨ ͨѶ×÷Õߣ©
1. Kong F, Tong R, Jia L, Wei W, Miao X, Zhao X, Sun W, Yang G, Zhao C*.OVCA1 inhibits the proliferation of epithelial ovarian cancer cells by decreasing cyclin D1 and increasing p16, Mol Cell Biochem, 2011,354(1-2):199-205
2. κΡ, ÀîÑÒ, ʯÃô, ÕÅÓ¨, ÂÀÙ», ¹ùÄÈ, ÕÔ´ºÑÞ. ÒÖ°©»ùÒòOVCA1 A34DÍ»±ä¶ÔÆäÉúÎï°ëË¥ÆÚµÄÓ°Ïì, Öйú΢Éú̬ѧÔÓÖ¾, 2016, 28(7):778-780
3. ÃçСÑÞ, ¿×·±¶·, ËïÔÃ, ÀîÑÒ, À»ª, κΡ, ÕÔ´ºÑÞ. HPV16 E6¶ÔHeLaϸ°ûÖÐRap1GAPµ°°×ˮƽϵ÷µÄÑо¿. Öйú΢Éú̬ѧÔÓÖ¾, 2015,05:527-530+538.
4. ÃçСÑÞ, ¿×·±¶·, ʯÃô, Bos JL, ÕÔ´ºÑÞ. ½Íĸ˫ÔÓ½»ÏµÍ³É¸Ñ¡ÓëRapGAPÏ໥×÷Óõĵ°°×ÖÊ. Öйú΢Éú̬ѧÔÓÖ¾,2015,06:668-671+676.
5. ÃçСÑÞ, ¿×·±¶·, ʯÃô, À»ª, ÕÔ´ºÑÞ. HPV16/18¸ÐȾµ¼Ö¹¬¾±°©µÄ·Ö×Ó»úÖÆÑо¿. Öйú΢Éú̬ѧÔÓÖ¾,2015,10:1152-1155.
6. ʯÃô, κΡ, ËïÔÃ, ËÎÁá, ¿×·±¶·, ÕÔ´ºÑÞ. µ°°×øÌåÒÖÖƼÁMG132 ¶ÔHelaϸ°ûÔöÖ³µÄÒÖÖÆ×÷ÓÃ. ÖйúÉúÎïÖÆƷѧÔÓÖ¾, 2017.
7. ÃçСÑÞ, ʯÃô, ÀîÑÒ, ÕÔÎĽ¿, ¿×·±¶·, ÕÔ´ºÑÞ. ʯÀ¯ÇÐƬÖÐOVCA1µÚ2ÍâÏÔ×ÓPCR-SSCP¼ì²â·½·¨µÄ½¨Á¢. ÖйúÀÏÄ겡ѧÔÓÖ¾. 2017.